Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Manufacturing

Warning Letters Mount As FDA Completes Initial Inspections Of Under-The-Radar Facilities

Later this year, FDA expects to complete initial inspections of every facility that manufactures drugs for the US market. As the agency visits under-the-radar facilities recently targeted as part of an effort to leave no site uninspected, it is finding that they are more likely to have serious drug GMP issues.

Manufacturing Quality United States

Latest From Manufacturing

Dealing With Brexit: EMA Offers Firms Advice On More Thorny Questions

The European Medicines Agency has updated its guidance on Brexit to offer companies more advice on the regulatory changes they will need to make in areas like transfers of MAs, rapporteurships and orphan designations, multi-country packs, and Article 58 opinions.

Brexit United Kingdom

PIC/S Adopts New Guide On Cross-Contamination, Transposes EU GMP Requirements

The group representing international pharmaceutical inspectorates, PIC/S, has issued new guidance on controlling cross-contamination in shared facilities. It has also transposed several EU guidelines on good manufacturing practice that non-EEA participating authorities can adopt on a voluntary basis. 
International Europe

FDA Lauds St. Gallen's Findings On 10 Metrics For Ensuring Drug Quality

US FDA touts new evidence that high performance of pharmaceutical manufacturing sites on 10 quality maturity metrics correlates with robust pharmaceutical quality systems, operational excellence and good business. An FDA-funded study by St. Gallen also finds that low performance, on the other hand, correlates with manufacturing problems.

United States Manufacturing

ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA

Generic industry officials ask that information requests and discipline review letters be issued during ANDA amendment assessments, but the US agency says they are not allowed in GDUFA II.

FDA Generic Drugs

How Manufacturers Need To Shore Up Fragile Supply Chains To Prevent Antibiotics Shortages

The potential of an impending “apocalypse” of antibiotic drug shortages means that the pharmaceutical industry should pay careful attention to managing fragile supply chains for these drugs. A report details how manufacturers can manage these supply chains to avert potential shortages.

Manufacturing Infectious Diseases

US FDA Crossing Off More Foreign OTC Firms On Globalization Checklist

FDA issued 39 warning letters to OTC drug facilities, most of them outside the US, in 2017, a number significantly boosted by an initiative to inspect a total of 1,000 foreign drug manufacturers from January 2017 through September 2019 , says CDER compliance director Donald Ashley. Many GMP violations behind FDA's warning letters concerned “rudimentary" requirements.

Consumer Manufacturing
See All